Axsome Therapeutics AXSM Cash Flow Statement (2015-2026)

NASDAQ AXSM
$207.22 -1.13 (-0.54%)
As of: Sep 4, 2026 · 2:31 PM EDT
Reported Financials

Axsome Therapeutics Quarterly Cash Flow Statement

Periods 46 quarters
Latest Jun 2026

Axsome Therapeutics reported cash from operations of -$32.95M and free cash flow of -$33.40M for the quarter ended Jun 2026, down 1.6% year over year. This cash flow statement covers 46 quarters of results from Mar 2015 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-34.88M-33.98M-39.63M-41.44M-44.82M-61.24M-11.24M-67.17M-62.18M-98.64M-68.36M-79.34M-64.60M-74.91M-59.41M-47.93M-47.23M9.35M-64.54M-51.31M
Share-based CompensationStock Comp.
5.73M5.89M7.60M6.52M6.54M10.77M12.94M15.92M16.37M18.91M20.19M21.38M21.66M21.99M23.87M24.61M23.10M22.73M82.80M68.30M
Gains from Investment SecuritiesGains Investment
Cash from OperationsCash from Ops.
-26.78M-28.84M-32.65M-33.54M-22.76M-27.56M-5.82M-55.35M-53.55M-30.36M-53.47M-30.11M-18.63M-26.20M-43.38M-32.42M1.05M-18.65M-20.70M-32.95M
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles
0.14M0.23M0.28M0.30M0.25M0.35M0.58M0.64M0.29M0.45M0.62M0.26M0.32M0.71M0.67M0.54M0.68M0.55M0.68M1.16M
Amortization of Deferred ChargesAmort. Deferred Charges
Change in Working Capital
Change in ReceivablesChange Receivables
4.13M17.40M7.09M22.62M11.01M16.41M6.62M18.91M3.75M17.91M19.40M37.43M-2.32M27.96M26.60M26.40M
Change in InventoryChange Inventory
0.29M1.32M3.62M1.31M-1.66M4.89M0.10M-0.69M-1.29M1.13M0.25M1.78M4.99M3.64M3.11M5.89M
Change in Account PayablesChange Payables
1.77M-0.23M-0.55M6.84M-6.59M25.76M-2.83M7.19M-13.86M11.58M13.11M7.55M2.91M7.74M13.66M5.97M-37.40M11.31M41.16M-27.73M
Change in Accured ExpensesChange Accured Exp.
0.28M-1.15M1.69M5.49M23.54M13.20M7.14M3.96M13.98M11.36M-8.41M33.49M5.32M25.67M0.82M21.50M54.25M7.17M17.23M46.61M
Investing Activities
Capital ExpendituresCapex
0.26M451.000.21M0.24M0.07M0.18M0.07M0.13M0.37M0.01M0.10M0.05M0.09M0.03M0.34M0.01M0.06M0.07M0.12M0.45M
Cash from Investing ActivitiesCash from Investing
-0.26M-451.00-0.21M-53.24M-0.07M-0.18M-0.07M-0.13M-0.37M-0.01M-0.10M-0.05M-0.09M-0.03M-0.34M-0.01M-0.06M-0.07M-0.12M-0.45M
Financing Activities
Other financing activitiesOther financing
0.44M1.09M0.18M0.18M3.06M2.83M0.39M6.57M4.32M1.15M2.50M17.04M
Cash from Financing ActivitiesCash from Financing
0.44M0.69M31.10M75.46M176.95M1.07M51.56M246.08M33.37M-0.00M-1.19M14.38M30.41M14.24M29.27M34.54M21.27M16.39M2.99M48.15M
Change in Capital Stock
Net Shares Issued and RepurchasedNet Shares Issued
2.04M1.22M2.22M1.54M2.53M0.90M1.22M0.27M0.39M0.02M
Net Equity Issued and RepurchasedNet Equity Issued
0.22M31.01M32.55M180.20M211.30M33.75M13.10M16.42M19.65M32.63M9.95M5.67M6.34M13.47M
Additional items
Change in Cash
-26.60M-28.15M-1.76M-11.31M154.13M-26.68M45.67M190.60M-20.55M-30.37M-54.75M-15.78M11.68M-11.99M-14.44M2.11M22.26M-2.34M-17.83M14.74M
Free Cash FlowFCF
-27.03M-28.84M-32.87M-33.78M-22.82M-27.74M-5.89M-55.48M-53.92M-30.37M-53.56M-30.16M-18.72M-26.23M-43.71M-32.44M0.99M-18.72M-20.82M-33.40M
Net Cash FlowNCF
-26.60M-28.15M-1.76M-11.31M154.13M-26.68M45.67M190.60M-20.55M-30.37M-54.75M-15.78M11.68M-11.99M-14.44M2.11M22.26M-2.34M-17.83M14.74M